Rize Oncology Inc.
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.09% | -7.42% | 316.77% | -22.58% | -25.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.88% | -47.52% | 212.27% | -23.58% | -24.85% |
| Operating Income | -67.88% | 47.52% | -212.27% | 23.58% | 24.85% |
| Income Before Tax | -84.19% | 46.17% | -366.30% | 23.11% | 29.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.19% | 46.17% | -366.30% | 23.11% | 29.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.19% | 46.17% | -366.30% | 23.11% | 29.42% |
| EBIT | -67.88% | 47.52% | -212.27% | 23.58% | 24.85% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 2.70% | 45.68% | -450.00% | 3.45% | 11.90% |
| Normalized Basic EPS | 0.00% | 46.00% | -425.00% | 5.56% | 11.54% |
| EPS Diluted | 2.70% | 45.68% | -450.00% | 3.45% | 11.90% |
| Normalized Diluted EPS | 0.00% | 46.00% | -425.00% | 5.56% | 11.54% |
| Average Basic Shares Outstanding | 88.23% | -1.26% | -20.72% | -20.13% | -19.96% |
| Average Diluted Shares Outstanding | 88.23% | -1.26% | -20.72% | -20.13% | -19.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |